Key 2025 EAU Guideline Focuses that came up in FRCS exams!
Estimated reading time: 8 minutes
The European Association of Urology (EAU) publishes new evidence-based guidelines annually, and the 2025 updates introduce several important changes across prostate cancer, NMIBC, renal cancer, stones, functional urology, and paediatric urology. These changes not only impact clinical practice — they are also high-yield topics for the FRCS Urology exam.
Here’s your concise, exam-focused summary of the top 10 EAU 2025 revisions.
🔎 1. Prostate Cancer: MRI-First and Risk-Based Biopsy Refinement
EAU 2025 reinforces the MRI-first approach for suspected prostate cancer. Importantly, biopsy can now be omitted in men with PI-RADS ≤2 and low clinical suspicion (e.g. PSA density <0.20), using shared decision-making and PSA follow-up.
PSMA PET/CT is now the preferred staging tool (if available) for intermediate/high-risk cases and biochemical recurrence, replacing CT and bone scan in most scenarios.
🩺 2. Bladder Cancer: Risk-Based Care and BCG Shortage Guidance
Molecular subtyping is recognised for prognostic and research purposes, but does not yet replace clinical staging to determine treatment.
EAU 2025 also supports reduced-dose BCG or alternative intravesical chemotherapy (e.g. mitomycin C, gemcitabine) in light of global BCG shortages. Early radical cystectomy remains the standard for BCG-unresponsive high-risk NMIBC.
🧬 3. Renal Cancer: Adjuvant Immunotherapy and Surgical Strategy
Pembrolizumab is now supported as adjuvant therapy in high-risk patients after nephrectomy based on KEYNOTE-564.
Nephron-sparing surgery remains the goal for T1 and selected T2 tumours where feasible. For metastatic RCC, cytoreductive nephrectomy is generally reserved for select cases after systemic therapy response.
🪨 4. Urolithiasis: MET and Imaging Follow-Up
EAU 2025 still endorses α-blockers (e.g. tamsulosin) as medical expulsive therapy for distal ureteric stones >5 mm (weak recommendation).
Follow-up after stone clearance should begin with KUB and/or ultrasound at 4–6 weeks; low-dose CT is reserved for uncertainty or complications.
🌡️ 5. Male LUTS & BPH: Combination Therapy and Targeted MIST Use
Combination therapy (α-blocker + 5ARI) remains the standard for moderate–severe LUTS in men with a prostate volume >40 mL.
Minimally invasive treatments (MISTs) like Rezūm are recognised as conditional options in selected patients. Evidence for other MISTs (e.g., iTIND) remains limited.
💔 6. Erectile Dysfunction: Cardiometabolic Screening Priority
ED work-up now explicitly incorporates cardiometabolic risk evaluation — reinforcing ED as a sentinel marker of vascular disease.
Low-intensity shockwave therapy (Li-ESWT) is a conditional second-line option for vasculogenic ED not responding to PDE5 inhibitors.
🧫 7. Male Infertility: Selective SDF Testing and Varicocele Criteria
Sperm DNA fragmentation (SDF) testing is not routine — it may be considered only in selected cases (e.g., unexplained infertility, failed ART).
Varicocele repair is reserved for clinical grade varicoceles with abnormal semen parameters. The subinguinal microsurgical approach is preferred.
🎗️ 8. Testicular Cancer: Imaging De-Escalation in Stage I Seminoma
TRISST-based imaging schedules allow for fewer scans and MRI instead of CT during stage I seminoma surveillance.
Post-chemotherapy RPLND is reserved for selected cases with persistent masses.
🚻 9. Urinary Incontinence: Standard Sling Care and Male Treatment Algorithms
Mid-urethral slings (MUS) remain the standard of care for female stress urinary incontinence, with proper mesh-related counselling.
In men, slings are appropriate for mild to moderate leakage; use an artificial urinary sphincter (AUS) for moderate–severe or post-radiotherapy incontinence.
👶 10. Paediatric Urology: Streamlined VUR and Hydronephrosis Algorithms
Low-grade vesicoureteral reflux (VUR) is usually managed conservatively. Antibiotic prophylaxis is reserved for recurrent febrile UTIs or high-risk patients.
Hydronephrosis evaluation follows a “ultrasound first” model, using MAG-3 renography selectively for functional assessment.
💡 Final Thoughts: Turn These Updates into Exam-Ready Knowledge
These changes highlight the broader trend toward precision, value-based care in urology. For FRCS candidates, use this as a framework for viva revision — linking knowledge to pathways, rationale, and evidence.
Bookmark or download the EAU Guideline summaries and integrate these updates into practice and exam prep.
Author: SmashUrology Team